Positive opinion based on results of Phase 3 C-POST trial that show Libtayo significantly reduced the risk of disease recurrence or death by 68% compared to placebo (hazard ratio: 0.32; 95% confidence ...

The combination of Lenvima (lenvatinib) and Keytruda (pembrolizumab) with chemotherapy did not help patients with metastatic ...

How Interdisciplinary Care Helped a Dental Patient Recover from Mouth Cancer ...

Although exposure to ultraviolet rays is a primary cause of skin cancer, factors such as your age, sex, and smoking habits also may contribute to developing this health issue.

Regeneron Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its blockbuster cancer drug Libtayo for certain ...

Lenvatinib plus pembrolizumab and chemotherapy did not significantly improve overall survival in metastatic ESCC compared to pembrolizumab and chemotherapy alone. Median overall survival was 17.6 ...

Dr Anjali Pathak discusses four cases of skin cancer or pre-cancer - involving potentially malignant skin lesions - and their management ...

Regeneron (REGN) announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for ...

New research published in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, ...

Like the surface of the moon, new research published today in Cell finds the existence of craters on the surface of melanoma ...

Blocking structural changes may restore the effectiveness of the cancer drug venetoclax, according to Rutgers Health ...